Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.
The company plans to meet with the FDA before the end of the year to discuss the way forward, including a pivotal study it hopes to launch in 2023 in uncontrolled and resistant hypertension.
The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.
The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.
The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.